Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab
combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will
provide a higher level of clinical evidence-based evidence for the clinical treatment of
recurrent GBM, and fill the guidelines for the treatment of recurrent GBM.